TrialReader


BALance: ARDS Deconvolution by Bronchoalveolar Lavage Multiomics and Radiomics

NCT07633366 — Recruiting, 130 participants, Medical University of Vienna

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Check the BALance: ARDS Deconvolution by Bronchoalveolar Lavage Multiomics Profiling and Radiomics

RegistryNCT07633366, acronym BALance
StatusRecruiting
Study typeObservational
Enrollment130 (Estimated)
SponsorMedical University of Vienna (Other)
ConditionsARDS (Acute Respiratory Distress Syndrome)
Interventionssampling blood, Lavage with physiologic saline solution (Diagnostic test)
Datesstart 2026-07-01 (estimated), primary completion 2029-06-01 (estimated), completion 2030-06-01 (estimated), first posted 2026-06-08, last updated 2026-07-10
Locations1 site in Austria

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for ARDS (Acute Respiratory Distress Syndrome) All trials of sampling blood All trials of Lavage with physiologic saline solution

-Summary

Acute respiratory distress syndrome (ARDS) is a major contributor to ICU mortality and is characterised by hypoxaemia and pulmonary oedema. Pathomechanisms include barrier breakdown, immunopathology, haemostatic derailment and dysbiosis; however, the actual sequence of events and how they cumulatively lead to lung failure remains unclear. Although ARDS is frequently triggered by pneumonia, it can also occur as a result of trauma, aspiration or non-pulmonary causes. Importantly, ARDS is highly heterogeneous; growing evidence points to aetiology-specific pathomechanisms - a circumstance that explains why attempts to develop specific drugs or timely diagnostic markers have so far failed.

A comprehensive analysis of key microenvironmental and haemostasis-related parameters of the lung, combined with multidimensional quantitative image features derived from chest CT scans (radiomics), will enable us to i) identify ARDS phenotypes with different biological characteristics and ii) generate new hypotheses regarding aetiology- or subgroup-specific mechanisms, molecular markers and therapeutic options.

Our approach is based on ICU management of our patients guided by bronchoalveolar lavage fluid (BALF). Together with previously sampled cases and new samples collected as part of this study, our cohort will consist of patients with i) COVID-19-associated ARDS, ii) ARDS associated with other viral pneumonia, iii) ARDS associated with bacterial pneumonia, and iv) ARDS of non-pulmonary origin. Bacterial and fungal co-infections and superinfections are recorded in all patients and taken into account in the stratification. Patients with pneumonia without ARDS, as well as ventilated patients without underlying lung disease, serve as controls. To characterise the microbial lung microenvironment, the investigators combine data from routine microbiological diagnostics with microbiome sequencing and metabolomics. In addition, the investigators conduct comprehensive and longitudinal immune and haemostatic profiling by regularly analysing immune cells, cytokines and parameters of immune thrombosis in BALF and blood. Multi-omics integration then identifies phenotypic subgroups by merging all multimodal datasets - including radiomics. Selected samples from identified clusters are then further characterised using single-cell sequencing to uncover specific features/markers and pathomechanisms of the respective ARDS subtypes.

Although it is clear that the pathogenesis of ARDS is multifactorial, comprehensive studies that integrate all relevant parameters are rare. Radiomics is increasingly recognised as a powerful tool for capturing the clinical status of ARDS in detail; however, to date, this imaging data has not been systematically linked to other omics readouts. The investigators aim to bridging this gap by conducting a thorough investigation across various ARDS aetiologies in the present study, incorporating all identifiable key factors.

Our interdisciplinary team comprises basic immunologists, infectious disease and computational biologists, as well as clinicians with expertise in ARDS, infectious diseases, immunothrombosis and radiology.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
COVID-19 ARDSDiagnostic Test: sampling blood; Diagnostic Test: Lavage with physiologic saline solutionCOVID-19 ARDS
Pneumonia-induced ARDSDiagnostic Test: sampling blood; Diagnostic Test: Lavage with physiologic saline solutionPneumonia-induced ARDS
Severe pneumonia but no ARDSDiagnostic Test: sampling blood; Diagnostic Test: Lavage with physiologic saline solutionSevere pneumonia but no ARDS
Non-pulmonary origin ARDSDiagnostic Test: sampling blood; Diagnostic Test: Lavage with physiologic saline solutionNon-pulmonary origin ARDS
No lung pathologyDiagnostic Test: sampling blood; Diagnostic Test: Lavage with physiologic saline solutionNo lung pathology
  • sampling blood (Diagnostic test): blood will be drawn from patients on day 1 and once a week until discharge/withdrawal/death
  • Lavage with physiologic saline solution (Diagnostic test), also known as Mini-BALF: mini-BALF using a physiologic saline soluation will be performed on day 1 and once a week until discharge/withdrawal/death

+Outcome measures

Primary outcomes

  • ARDS phenotypes [4 years]: The application of multi-omics cluster analysis to reveal any distinct ARDS phenotypes or subgroup-specific characteristics.

Secondary outcomes

  • Lung Microbiome Composition Analysis via 16S rRNA Gene Sequencing of Bronchoalveolar Lavage (BAL) Fluid [4 years]: Differences in the microbial community composition (alpha diversity, beta diversity, and taxonomic abundance at phylum/genus level) of the lower respiratory tract microbiome in intensive care patients with ARDS
  • Metabolomic Profile of Bronchoalveolar Lavage Fluid and Plasma [4 years]: Differences in the metabolomic profile (relative concentrations of annotated metabolites and pathway-level scores) in bronchoalveolar lavage (BAL) fluid and plasma between ARDS subgroups (with vs. without bacterial/fungal co-/superinfection). Metabolomic measurements will be performed using the METAB02, AMINO01, and LIPID01 or other appropriate packages. Samples will be analyzed via mass spectrometry to quantify a wide range of analytes, including various amino acids, lipids and their subclasses, and metabolites such as pyruvate, lactate, citrate, and succinate.
  • Inflammatory Cytokine Profile in Bronchoalveolar Lavage Fluid and Plasma [4 years]: Concentrations of predefined pro- and anti-inflammatory cytokines (e.g., IL-6, IL-8, TNF-α, others according to panel) in BAL fluid and plasma of ARDS patients, and detection of differences between ARDS subgroups (with vs. without bacterial/fungal co-/superinfection) by Multiplex bead-based immunoassay or ELISA panels (e.g., Luminex, electrochemiluminescence).

+Eligibility

Sex: All, ages: 18 Years to any, accepts healthy volunteers

Inclusion Criteria:

* male and female
* aged 18 years or over
* signed consent form
* depending on the study group: Confirmed ARDS according to the Berlin criteria (see below, Groups B and D) Confirmed severe CAP requiring mechanical ventilation and intensive care (see below, Groups B and C) Ventilated patients without signs of ARDS (see below, Group E)

Exclusion Criteria:

\- under 18 years of age

+Locations (1)

FacilityCityCountryStatus
General Hospital of Vienna, Medical University of ViennaVienna, State of ViennaAustriaRecruiting

+Investigators

My Notes